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Objectives: The aim of the study was to combine clinical results from the European Cohort of the REVERSE study and costs
associated with the addition of cardiac resynchronization therapy (CRT) to optimal medical therapy (OMT) in patients with mild
symptomatic (NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac dyssynchrony in Spain.
Methods: A Markov model was developed with CRT + OMT (CRT-ON) versus OMT only (CRT-OFF) based on a retrospective
cost-effectiveness analysis. Raw data was derived from literature and expert opinion, reflecting clinical and economic
consequences of patient’s management in Spain. Time horizon was 10 years. Both costs (euro 2010) and effects were
discounted at 3 percent per annum.
Results: CRT-ON showed higher total costs than CRT-OFF; however, CRT reduced the length of hospitalization in ICU by 94
percent (0.006 versus 0.091 days) and general ward in by 34 percent (0.705 versus 1.076 days). Surviving CRT-ON patients
(88.2 percent versus 77.5 percent) remained in better functional class longer, and they achieved an improvement of 0.9 life
years (LYGs) and 0.77 years quality-adjusted life years (QALYs). CRT-ON proved to be cost-effective after 6 years, except for
the 7th year due to battery depletion. At 10 years, the results were €18,431 per LYG and €21,500 per QALY gained.
Probabilistic sensitivity analysis showed CRT-ON was cost-effective in 75.4 percent of the cases at 10 years.
Conclusions: The use of CRT added to OMT represents an efficient use of resources in patients suffering from heart failure in
NYHA functional classes I and II.
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According to the European Society of Cardiology (ESC) there
are at least 15 million patients with heart failure (HF) in a total
population of 800 million people in Europe (1). The prevalence
of HF ranges between 2 and 3 percent, and rises sharply at
75 years of age, being the prevalence in 70- to 80-year-old
patients between 10 and 20 percent (1). HF is responsible for a
5 percent of acute hospital admissions; it is present in 10 percent
of patients in hospital beds, and accounts for approximately 2
percent of national expenditure on health, mostly due to the cost
of hospital admissions. Overall, 50 percent of patients with HF
die after 4 years; moreover, 40 percent of patients admitted to
hospital die or are readmitted within 1 year (1).
In Spain, at least 2 percent of the population over 40 years
old suffers from HF, 6 to 10 percent of those patients being over
60 years old (2). The three leading causes of death in Spain in
2008 classified by large groups were cardiovascular disease (re-
sponsible for 31.7 percent of all deaths), tumors (26.9 percent),
and respiratory system diseases (11.4 percent) (3). Specifically,
HF is the third leading cause of cardiovascular death after heart
disease and cerebrovascular disease. Additionally, it is the only
cardiovascular disease that currently presents a continuous in-
crease in incidence and prevalence (4). From 2000 to 2007,
the prevalence of HF increased steadily from 895 to 2,126 per
100,000 person-years, and the incidence augmented from 296
per 100,000 person-years in 2000 to 390 per 100,000 person-
years in 2007 (5). It is a progressive and fatal disorder which
has an unsatisfactory prognosis even with proper treatment.
Drug therapy for HF has used multiple strategies that in-
clude and combine angiotensin-converting enzyme inhibitors,
angiotensin II receptor antagonists (or angiotensin receptor
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blockers), aldosterone antagonists and beta blockers. However,
a large number of patients have a poor quality of life and present
high mortality rates. They are non-responders despite adequate
medication (6;7). New targets for therapy are being identified,
many of which are focused on specific groups of HF patients
(HF with preserved ejection fraction or with chronic kidney
disease or with Nephropathy Due to Type 2 Diabetes) rather
than the whole population. Cardiac resynchronization therapy
(CRT), which aims to restore synchronous cardiac contraction,
is one such therapy that attempts to treat patients with cardiac
dyssynchrony (1;7). It has been estimated that 20 to 30 percent
of patients with symptomatic HF and 10 percent of patients with
no selectedHF suffer from intraventricular conduction disorders
and could benefit from CRT (8).
CRT has been shown to be clinically effective in patients
with New York Heart Association (NYHA) classes III or IV
HF, left ventricular dysfunction and prolonged QRS duration
(1). In addition, recent trials have confirmed the clinical ef-
ficacy of CRT in patients with either asymptomatic or mild
HF (NYHA I/II), with evidence that CRT may prevent dis-
ease progression by reducing clinical outcomes through reverse
left ventricular remodeling (9;10). Specifically, the REVERSE
study has demonstrated that CRT improves clinical response
in NYHA functional class (I–II), included in this composite
response structure and function of the left ventricle in mildly
symptomatic or asymptomatic patients with left ventricular dys-
function andmarkers of cardiac dyssynchrony. CRT has demon-
strated to be cost-effective in this patient group from the British
perspective, with incremental cost-effectiveness ratios (ICER)
ranging from €7,538 to €18,017 (11).
In this sense, we aim to assess the efficiency of CRT among
this population by conducting an economic analysis of CRT
based on the REVERSE study from the Spanish Health System
perspective.
METHODS
A cost-effectiveness analysis of cardiac resynchronization ver-
sus conventional (optimal medical therapy, OMT) care has been
performed using a Markov model based on data from the Eu-
ropean REVERSE study, data from the literature and expert
opinion to allocate the economic consequences of each option
through a 10-year comparison.
The REVERSE study was designed to validate whether
CRT in combination with OMT is beneficial in mildly symp-
tomatic (NYHA I-II) or asymptomatic patients with left ven-
tricular dysfunction and markers of cardiac dyssynchrony to
prevent disease progression in the long term. The study was
undertaken in centers of the United States and Europe but only
the latter performed a 2-year follow-up.
In this European cohort, a total of 287 participants were
randomized (2:1) either to the CRT group (CRT-ON) (n = 180)
or control group (CRT-OFF) (n = 82), and followed-up for 24
months.
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Figure 1. Markov chain used to model the 10-year follow-up period. NYHA, New York Heart Association
classification.
Regardless of the assigned group, all patients were treated
with OMT in accordance with HF guidelines, and after assess-
ing the appropriateness of participation in the study, defibrilla-
tors were implanted to those patients who needed them (ICD /
CRT-D).
Study Design
Type of Analysis. A cost–effectiveness analysis was carried out to
compare the alternative scenarios (with/without CRT) using
two different effectiveness indicators: life years gained (LYG)
and quality-adjusted life-years (QALY) taking into account that
different strategies were offered depending on whether patients
needed to have defibrillators implanted or not. Data on health-
care resources were adjusted from the REVERSE-EU study
with an expert panel consisting of three Spanish cardiologists
from different institutions. Clinical opinion was compiled us-
ing a structured questionnaire in two interviews, the first ex-
ploratory and the second for validation and consensus. Clini-
cal authors were selected according to clinical experience and
national and international research achievements. To retain in-
ternal consistency, this dataset was analyzed considering a 24-
month randomized follow-up. Results were finally displayed as
cost per LYG and cost per QALY gained with or without CRT
(CRT-ON versus CRT-OFF).
The analysis was performed from the Spanish National
Health System perspective and only direct medical costs were
included over a 10-year time horizon. Both costs and outcomes
were discounted at 3 percent per annum.
Modeling. A decision analytic model was developed to estimate
the costs and the underlying disease process of patients with
mildly asymptomatic HF. Health states were defined by NYHA
class (I-III) and death. NYHA class IV was not included in
the model because no patient was classified as being in NYHA
IV at any follow-up visit. Costs and utilities were attached to
each health state and patients in each treatment arm accrued
costs and benefits as they passed through these states. Time was
measured in discrete units of 1 month (1-month cycles) and a
10-year time horizon was used (Figure 1). Costs were expressed
in Euro 2010.
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Table 1. Unit Cost by Resource Used (Base Case and Range for Sensitivity Analysis)
CRT CRT-D ICD Source
Device Costs €4,544.00
(€4,433.66-€5,792.81)
€20,259.00
(€20,017.79-€21,479.08)
€17,263.77
(€16,513.56-€17,745.88)
(13)
Leads €1,605.00
(€1,444.50-€1,765.50)
€2,683.00
(€2,414.70-€2,951.30)
- Internal data Medtronic
Initial implantation €2,729.07
(€2,577.01-€3,936.16)
€2,729.07
(€2,577.01-€3,936.16)
€711.66
(€640.50-€782.83)
(14) Base case CRT/CRT -D is an average
of DRG 116, 115 and 851. Base Case
ICD is DRG 849
Device replacement procedure €963.52
(€770.81-€1,156.22)
€963.52
(€770.81-€1,156.22)
€711.66
(€640.50-€782.83)
(14). Base case CRT/CRT-D is an average
of DRG 118, 115 and 851. Base Case
ICD is DRG 849
ICU ward (per day) €1,470.10 (€1,127.25-€1,764.12) (14)
General ward (per day) €723.56 (€578.85-€868.27) (14)
Cardiology visits (per visit) €59.69 (€47.75-€71.63) (14)
GP visits (per visit) €23.95 (€20.10-€27.80) (14)
Hospitalization Costs €3,362.29 (€3,320.61-€3,389.19) (14) DRG 127
CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy + defibrillator; ICD, implantable cardioverter defibrillator; ICU, intensive care unit; GP, general
practice; DRG: diagnosis-related group.
The whole analytical model was developed in Microsoft
Office Excel 2007 (Microsoft Corporation, Redmond, WA) us-
ing a three stage process, although regressions were calculated
in SAS v9.1 (SAS Institute Inc., Cary, NC) using data from the
REVERSE study. First, at any given time point, the surviving
proportion of the original cohort was derived. Second, for the
same time point the distribution across three NYHA classes was
derived for all surviving patients. Finally, the derived propor-
tions in each health state were multiplied by the relevant cost
and utility estimates to derive monthly values. All totals were
summed over the time horizon to generate total intervention
values.
Model Parameters
Probabilities. A multinomial logistic regression was used to esti-
mate NYHA mix over time. NYHA class was the dependent
variable in all analyses and, in addition to a constant term, anal-
yses were carried out using different predictor variables—time,
time squared, exp(time), log(time). All analyses were clustered
by patient. On the basis of a visual check of goodness-of-fit to
thewithin-trial data, and the opinion of the project steering com-
mittee concerning the plausibility of long-term predicted state
occupancy, log(time) was used in the final models. Baseline
values of model probabilities used for estimating the clinical
consequences of the alternative scenarios were 0.17 for NYHA
I, 0.84 for NYHA II and 0.00 for NYHA III (9).
Mortality was low in the REVERSE-EU cohort. Therefore,
to maximize the amount of information available to inform pa-
rameterization, all follow-up data for European patients initially
randomized to the CRT-ON arm were used. For patients in the
CRT-OFF arm only data for the first 2 years post-randomization
were available to inform model parameters.
A range of parametric survival functions were fitted to time-
to-event data with using the treatment as a covariate. On the
basis of estimated log-likelihood values, a Weibull proportional
hazard model was used.
Utilities. To translate LYG toQALY, a 0.93 (IC; 0.912; 0.96) utility
valuewas assigned for NYHA I patients, 0.78 (IC; 0.722; 0.842)
for NYHA II patients and 0.61 (IC; 0.591; 0.631) for NYHA
III patients (12).
Costs. Device costs were taken from Eucomed Q2 2009-Q1 2010
(13). Individuals in the CRT-OFF arm who received a CRT-D
device were allocated the cost of an ICD implant. The device
lifetime assumed was 6.5 years for CRT, 5.5 years for CRT-D,
and 6 years for ICD. The cost of all subsequent device replace-
ments was included in the model.
Because no data have been published on the Spanish costs
for the therapeutic options analyzed in this model, a micro-
costing strategywas used. Data on resources usedwere obtained
from three Spanish cardiologists (Table 1), while unit costs were
retrieved from the Spanish Health Costs Database (14) and from
the Spanish Drug Price Database (15). Costs were inflated to
2010 values, when necessary.
Sensitivity Analysis
A probabilistic sensitivity analysis was carried out with
all the parameter ranges from the model. A Monte Carlo
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Figure 2. Survival Analysis of CRT-ON and CRT-OFF. CRT, cardiac resynchronization therapy.
simulation analysis was performed, estimating costs and ben-
efits for a cohort of 10000 hypothetical patients to display
the cost-effectiveness plane, and building separate acceptability
curves to illustrate uncertainty. Current recommendations were
followed to derive the parameter distributions: method-of-
moments fitting was used to derive beta distributions for prob-
abilities based on frequency; because costs in the model are
mainly a function of the unit cost of the different surgical pro-
cedures, lognormal distributions were derived from total inter-
vention costs assuming a standard deviation of 10 percent from
mean values obtained using a microcosting strategy.
RESULTS
Use Resources and Costs
The introduction of CRT into the management of patients with
NYHA functional classes I and II HF provides and additional
cost of €16,629.23 over the 10-year period post-implantation.
However, the results of the hospitalizations analysis show
that the introduction of CRT reduces the length of stay in inten-
sive care unit (ICU) in 94 percent and the stay in general ward
in 34 percent. The average days in ICU is 0.091 for CRT-OFF
patients and 0.006 for CRT-ON patients, and in the same way,
the average length of stay in general ward is 0.705 and 1.076
for CRT-ON and CRT-OFF, respectively.
Overall survival at 10 years is 77.5 percent and 88.2 percent
for individuals in the CRT-OFF and CRT–ON arms respectively
(Figure 2). CRT-ON patients are in a mild NHYA longer than
CRT-OFF patients.
Efficiency and Cost-Effectiveness results
The Number Needed to Treat to save one life was 4.9, to avoid
a day in ICU 1,084 and to avoid a day in general ward 204.
After 6 years, CRT-ON was cost-effective, except for the
7th year due to device replacement costs for battery depletion.
In a 6-year period the results of the cost-effectiveness analysis
Table 2. Incremental Cost-Effectiveness Ratio of Cardiac Rresynchronization
Therapy at 10 Years
Life-year gained QALYs Costs
CRT-OFF 6.74 5.45 €23,177.30
CRT-ON 7.64 6.23 €39,806.53
Difference 0.90 0.77 €16,629.22
Cost per LY gained €18,430.92
Cost per QALY gained €21,500.48
CRT, cardiac resynchronization therapy; LY, life-year; QALYs, quality-adjusted
life-years.
demonstrate an ICER of €1,142/LYGs and an ICER in terms
of QALYs of €11,508/QALYs for patient management with
CRT. The cost-effectiveness analysis (Table 2) shows that the
introduction of CRT provides an additional effectiveness of 0.90
LYGs per patient in a 10-year period compared with non-CRT
patients. This value results in an ICER of €18,430.92/LYGs.
The corresponding gain in terms of QALYs is 0.77, with an
ICER of €21,500.48/QALY.
Supplementary Figure 1, which can be viewed online at
www.journals.cambridge.org/thc2013085, shows the accept-
ability curves of CRT-ON versus CRT-OFF scenarios. Using
the defined Spanish criteria of efficiency threshold for a new
technology (around €39,000 per QALY, data from year 2001
adjusted to 2010) (16), the probability of the introduction of
CRT being cost-effective is 75.4 percent for CRT-ON patients.
Moreover, for thresholds of €30,000, €35,000 and €45,000,
the probability of a cost-effective introduction of CRT is 65.54
percent, 71.9 percent, and 79.47 percent, respectively.
Robustness of results was tested varying individual parame-
ter values on model results. The model was sensitive to changes
in the proportions receiving an ICD and the associated costs
of implantation. Several alternative approaches to modeling
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the REVERSE trial data are explored, with none resulting in
an ICER above €34,000 per QALY gained. The results of the
probabilistic analysis show that taking into account the uncer-
tainty in the main variables of the Markov Model, starting the
treatment of OMT with CRT remains cost-effective versus the
other alternatives.
DISCUSSION
The use of CRT added to OMT represents an efficient use of
resources and a favorable option in patients suffering from
heart failure in NYHA functional classes I and II, with cost-
effectiveness ratios below the Spanish threshold from the 6th
year, except for the 7th year due to device replacement cost for
battery depletion.
Both efficacy and effectiveness for CRT had been widely
assessed and demonstrated for advanced congestive HF (classes
III and IV) unlike for NYHA classes I/II. In general, the effi-
ciency of CRT-P on NYHA III/IV patients is well known, with
several studies demonstrating an acceptable ICER against phar-
macological treatment such as COMPANION (17), or an exten-
sive cost-effectiveness analysis performed by NICE (National
Institute for Clinical Excellence) (18) with 5 years cumulative
data from several CRT studies (MIRACLE [19], CONTAK-CD
[20], MUSTIC-SR [21], CARE-HF [7;22], and COMPANION
[17]). Costs and benefits were derived from a Markov model
developed from the British NHS.
Additionally, Callejo et al. (6) evaluated the incremental
cost-effectiveness of CRT alone and CRT with implantable de-
fibrillator compared with standard care from the Spanish health-
care perspective. CRT-P appeared to be cost-effective while
CRT-D ICER was above the accepted threshold (€54,000).
Previous analyses of the COMPANION (17), CARE-HF
(7;22) trials and a Spanish adaptation of CARE-HF trials indi-
cated that both CRT-P and CRT-D devices are cost-effective in
patients with NYHA class III/IV (23). Mun˜oz et al. (23) ob-
served that patients treated with CRT+Standard Care showed
an average increase of 0.44 QALYs per patient, resulting in
an incremental cost-effectiveness ratio of €14,877 per QALY
gained at 5 years from the Spanish Health System perspective.
The effectiveness data from patients in our study is based on
one clinical trial. However, there are other studies, as MADIT-
CRT (10) and RAFT (24), showing a clinical improvement in
the introduction of CRT into slighter functional classes as well.
MADIT-CRT enrolled 1,820 patients in NYHA function class
I (15 percent) of ischemic etiology or II (84 percent) of any
etiology and sinus rhythm. Using a 2:3 randomization scheme,
731 patients were assigned to receive an ICD and 1,089 received
a CRT-D. During a mean follow-up of 2.4 years, the relative risk
of sustaining a primary endpoint (death from any cause and
non-fatal HF-related adverse events) was reduced by 34 percent
in the CRT-D treated group, a benefit attributable primarily to a
41 percent decrease in HF-related adverse events. The 3 percent
annual mortality was similar in both REVERSE and MADIT-
CRT studies groups.
At present time, Linde et al. (11) is the only cost-
effectiveness analysis developed for patients with mild HF from
the British NHS perspective. Our study was based on the British
model, therefore, the structure and methods are pretty similar
to the British study, although in our study the proportion of
patients with ICD was greater with CRT-ON (75 percent ver-
sus 66 percent) and lower with CRT-OFF (60 percent versus
72 percent). Compared with the Spanish analysis, the results
observed in both studies are similar, being the base case ICER
in the Linde et al. (11) study €12,172 per LYG, and €14,278
per QALY gained. The differences observed could be explained
by the fact that the relationship between unitary costs and drug
treatments differ among countries. Although we have included
general practice visits and more outpatient visit in NYHA III (3
versus 2 visits), Spanish costs per group were lower than British
costs, except in CRT group. This differencemay be explained by
device and leads cost. On the other hand, our analysis included
consumption of statins (62 percent to 67 percent), antiplatelet
(50 percent to 58 percent), anticoagulant (12 percent to 33 per-
cent), nitrates (17 percent to 27 percent), calcium antagonist (10
percent to 12 percent) and amiodarone (5 percent to 10 percent)
that Linde et al. (11) study did not include.
The ICERs presented in this study are higher than those
derived from the CARE-HF study (7;22). This is likely to be
a result of a 10-year rather than lifetime time horizon. If the
model would have been run for a lifetime the increased benefit
associated to delayed progression for NYHA III/IV would have
become more apparent. However, further work is required to
prove this hypothesis.
It is important to emphasize that the utilities used in our
model were different from those used by Callejo et al. (6), and
these differences could explain the divergence between conclu-
sions of both studies (25). Utility values used in this analysis are
based on observed utilities in United Kingdom (12), although
they are considered to be internationally feasible. However, util-
ities may be considered as a limitation in this study. Keeping in
mind the main use of measures related to quality of life in HF
that have been used as an outcome in clinical trials, extrapolat-
ing the study to the clinical practice could be difficult.Moreover,
in most clinical trials a single specific questionnaire was used,
usually the Minnesota Living with Heart Failure Questionnaire,
which may have hampered a broader vision of impaired Health
Related Quality of Life in this syndrome.
Several limitations are present in our study. First, we ex-
trapolate used effectiveness data from the REVERSE-EU study.
Therefore, main limitations come from assuming that the clin-
ical practice studied in the REVERSE trial was equal to the
Spanish clinical practice, and second, from presuming that
this therapy could be incorporated as a treatment for patients
with mild to moderate HF in Spain. However, clinical prac-
tice in Spain for these patients is similar to that in Europe,
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and patient’s age and clinical characteristics are similar, pre-
senting a high level of coincidence with those observed in the
REVERSE-EU clinical trial. As a consequence, the results ex-
posed through this study are likely to be close to reality.
Other limitation of the study could possibly lie in the per-
spective of an expert panel to adapt the use of resources. To
avoid potential bias, the use of resources was adapted for Spain.
Even more, three Spanish centers participated in the REVERSE
trial with an inclusion rate higher than other countries. On the
other hand, because the Spanish Cardiology Society does not
have specific guidelines for resynchronization, physicians based
their daily practice on the ESC guidelines where CRT is rec-
ommended for NHYA II. Additionally, CRT is being implanted
within this subgroup of patients with an implantation rate con-
siderably lower than other U.S. or EU countries, mainly due
to CRT initial costs, which represented a strong barrier for the
adoption of this therapy.
Our study only took into account direct costs incurred by the
Spanish healthcare system, but in real practice other costs asso-
ciated with or derived from the society do exist, like temporary
sick leaves or early retirements (productivity loss). Therefore,
should this study have considered indirect costs or the slowing
down of the disease progression resulting from an earlier incor-
poration of CRT, the ICERs would have been lower, and thus
CRT would have been considered a more efficient alternative.
A Spanish efficiency threshold for a new technology
is not defined, although the values assumed correspond to
€30,000/QALY and €30,000/LYGs (€ 2001) (16), proving that
CRT is a cost-effective intervention. Cost-effectiveness stud-
ies are valuable tools for comparing different therapeutic al-
ternatives and, therefore, are useful for decision making in the
framework of overall assessment of medical interventions and
healthcare technologies.
CONCLUSION
Finally, our results demonstrate that the implantation of CRT-
D in earlier stages of the disease represents a cost-effective
treatment alternative in patients with mildly symptomatic left
ventricular dysfunction andQRS≥ 120ms from the perspective
of the Spanish Health System.
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